Gesynta Pharma forms Scientific Advisory Board with international endometriosis experts

"We are incredibly proud to have gathered this renowned group of experts on our Scientific Advisory Board. Their combined knowledge will be critical as we advance the clinical development of vipoglanstat. These experts share our dedication to pioneering a new generation of non-hormonal treatments for patients suffering from this debilitating condition," says Patric Stenberg, CEO of Gesynta Pharma.

The Gesynta Pharma Scientific Advisory Board consists of:

Linda C. Giudice, MD, PhD, Chair of the SAB
Professor Giudice is a renowned reproductive endocrinologist and biochemist specializing in endometriosis and infertility and holds the titles of Distinguished Professor and Robert B. Jaffe, MD, Endowed Professor in Reproductive Sciences at the University of California, San Francisco (UCSF), USA. She also directs the UCSF Stanford Endometriosis Center for Discovery, Innovation, Training, and Community Engagement. Dr. Giudice is an authority integrating basic and clinical research, while remaining actively involved in treating patients having complex gynecological and reproductive conditions. Dr. Giudice is a former President of the World Endometriosis Society and the American Society for Reproductive Medicine (ASRM).

Christian Becker, MD
Dr. Becker is a Professor of Reproductive Sciences, Co-Director of the Oxford Endometriosis CaRe Centre, Oxford, UK, and a Consultant Gynaecologist. He serves as the Clinical Lead for the Oxford BSGE Endometriosis Centre, where he integrates patient care with innovative research to advance outcomes for women affected by the condition. As a leading expert in women's health, Dr. Becker focuses his research and clinical work on endometriosis, especially its connections to abdominal pain, adolescent gynecology, and subfertility.

Sawsan As-Sanie, MD, MPH
Dr. As-Sanie is the Robert K. Ferguson and Virginia A. Ferguson Professor of Obstetrics and Gynecology at the University of Michigan, Ann Arbor, Michigan, USA. She also serves as the Co-Chief of Gynecology, the Section Head of the Minimally Invasive Gynecologic Surgery Program, and the Director of the Endometriosis and Chronic Pelvic Pain Consultative Clinic. As a clinical and translational researcher, her primary focus is on the epidemiology, physiology, and treatment of endometriosis and other pelvic pain disorders. Her research aims to uncover the mechanisms that cause chronic pelvic and post-surgical pain, particularly in the context of endometriosis.

Marie-Madeleine Dolmans, MD, PhD
Dr. Dolmans is the Head of the Gynecology Research Unit at UCLouvain, Louvain, Belgium, Chief of Clinic at Saint-Luc University Clinics, Full Professor, and a Clinical Researcher with the FNRS (F.R.S.-FNRS). Dr. Dolmans is a leading expert in fertility preservation and reproductive surgery. Her research and clinical practice are dedicated to advancing methods for preserving fertility in patients facing treatments that could compromise their reproductive health. Her work primarily focuses on the cryopreservation and transplantation of human ovarian tissue, as well as on fibroids, endometriosis, and adenomyosis. She has extensive experience in research and development concerning endometriosis, including late-stage clinical development.

For more information, please contact:

Patric Stenberg, CEO
Tel: + 46 (0)733 83 66 70
E-mail: [email protected]

About Gesynta Pharma
Gesynta Pharma is a clinical-stage pharmaceutical company developing innovative treatments by targeting mPGES-1*, an important pro-inflammatory enzyme with a key role in endometriosis. Gesynta Pharma's research originated at Karolinska Institutet in Sweden.

The company's leading compound, vipoglanstat, is a selective mPGES-1* inhibitor being developed as a new non-hormonal, non-opioid treatment with disease-modifying potential. Vipoglanstat is currently in Phase 2 clinical trials for endometriosis - a painful, chronic inflammatory disorder affecting about 10% of women of reproductive age. The condition often leads to a markedly reduced quality of life, particularly as many existing treatments fail to provide adequate symptom relief. Vipoglanstat has shown potent mPGES-1 inhibition and a favorable safety profile across Phase 1 and 2 clinical trials. Furthermore, a preclinical proof-of-concept study in an advanced model of endometriosis demonstrated that vipoglanstat significantly reduced pain-related behaviors and endometriotic lesions.

A second drug candidate in the Gesynta Pharma portfolio, GS-073, is ready to enter clinical Phase 1 for the treatment of chronic inflammatory pain.

The company's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, XGen Venture, and other internationally renowned specialist investors.

For more information, please visit www.gesynta.se.

*mPGES-1: microsomal Prostaglandin E Synthase-1